Investigation of Blood Lipid Levels and Statin Interventions in Outpatients With Coronary Heart Disease in China - The China Cholesterol Education Program (CCEP)

被引:20
作者
Hu, Dayi [1 ]
Li, Jue [1 ]
Li, Xiankai [1 ]
机构
[1] Tongji Univ, Heart Lung & Blood Vessel Ctr, Shanghai 200092, Peoples R China
关键词
China Cholesterol Education Program (CCEP); Coronary heart disease; Lipids; Statins;
D O I
10.1253/circj.CJ-08-0417
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background The aim of the China Cholesterol Education Program is to investigate the blood lipid levels, the statin intervention and the rates of achieving the goal of low-density lipoprotein-cholesterol (LDL-C) level in Chinese outpatients with coronary heart disease (CHD). Methods and Results The Multicenter study recruited 4,778 outpatients with CHD. The mean level of LDL-C for the total outpatients was 2.93 +/- 1.00 mmol/L; 82.2% of the participants received statin therapy. The LDL-C levels were 3.06 +/- 1.08 mmol/L and 2.89 +/- 0.97 mmol/L in outpatients with high risk and very high risk, respectively (p<0.001). No significant difference was found about the rates of statin intervention in outpatients at high risk and very high risk (81.4% vs 82.5%, p>0.05). Though they had higher rates of statin intervention, only 36.2% of the high-risk outpatients achieved the target LDL-C level (<2.6 mmol/L); 10.9% of the very high risk outpatients achieved the optimal LDL-C level (< 1.82 mmol/L) suggested by NCEP ATP III. The rate of achieving the target level was only 42.2%, even though LDL-C <2.6 mmol/L was the goal for patients at very high risk. Conclusions Although the outpatients received a higher rate of statin therapy, the rates of achieving the target cholesterol level were lower. There is a significant gap between the guidelines and clinical practice in China. (Circ J 2008; 72: 2040-2045)
引用
收藏
页码:2040 / 2045
页数:6
相关论文
共 36 条
[1]
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[2]
2-S
[3]
[Anonymous], 2002, JAMA
[4]
Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
[5]
Chalmers J, 1999, J HYPERTENS, V17, P151
[6]
Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease [J].
Cheng, CWR ;
Woo, KS ;
Chan, JCN ;
Tomlinson, B ;
You, JHS .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (05) :528-535
[7]
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[8]
Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999 [J].
Critchley, J ;
Liu, J ;
Zhao, D ;
Wei, W ;
Capewell, S .
CIRCULATION, 2004, 110 (10) :1236-1244
[9]
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].
Downs, JR ;
Clearfield, M ;
Weis, S ;
Whitney, E ;
Shapiro, DR ;
Beere, PA ;
Langendorfer, A ;
Stein, EA ;
Kruyer, W ;
Gotto, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622
[10]
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [J].
Grundy, SM ;
Cleeman, JI ;
Merz, CNB ;
Brewer, HB ;
Clark, LT ;
Hunninghake, DB ;
Pasternak, RC ;
Smith, SC ;
Stone, NJ .
CIRCULATION, 2004, 110 (02) :227-239